Module

Clinical Need and Therapeutic Targets for New HCV Agents

Source: The Future of HCV: Small Molecules in Development for Chronic Hepatitis C

Clinical Need and Therapeutic Targets for New HCV Agents

Program Director: Raymond T. Chung, MD

Faculty:

Kenneth E. Sherman, MD, PhD

CME CREDIT INFORMATION

Release Date: 04/11/07

Expiration Date: 04/10/08

Physicians: maximum of 1.25 AMA PRA Category 1 Credits™

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss prospective therapeutic targets inherent in the mechanism of hepatitis C virus (HCV) viral replication
Explain the rationale for and potential utility of novel agents under development for the treatment of HCV
Describe HCV antiviral resistance that may develop with certain novel therapeutics

Topics covered include:

Introduction
Current Standard of HCV Therapy: Peginterferon and Ribavirin
The HCV Genome and Life Cycle
Virus Binding and Cell Entry
HCV RNA Pathway to the ER and IRES Binding to Ribosomes
HCV Polyprotein Synthesis and Processing
Assembly of the RNA Replication Complex (Replicase) and the Membranous Web
Initiation of Negative HCV RNA Synthesis and Synthesis of Positive HCV RNA
Virus Assembly and Release
Agents That Elicit a Nonspecific or Innate Immune Response to HCV
Viral Resistance to Emerging HCV Therapies
Future Directions
Summary: Implications for Clinical Practice

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.